# US 2022/0031631 A1 · High-purity peg lipids and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031631 A1
- Document ID: US20220031631A1
- Status: Published application
- Kind: A1
- Application number: 17/277,423
- Filed: 2019-09-19
- Published: 2022-02-03
- Earliest claimed: 2018-09-19
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Örn Almarsson; Jin Lim; Eugene Cheung; Jaclyn Milton
- Web page: https://patentgrep.com/patent/US20220031631A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- C08L 71/02: Polyalkylene oxides
- A61K 8/86: Polyethers
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- C08G 65/3322: {acyclic}
- C08G 65/48: Polymers modified by chemical after-treatment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations. Therefore, the present disclosure provides PEG lipids at a recommended purity, e.g., for use in formulations, such as LNP formulations. The present disclosure also provides LNPs comprising the high-purity PEG lipids, and methods for delivering therapeutic agents to a subject using the same.

## Claims

### Claim 1

A plurality of compounds of Formula (I):
or salts thereof, wherein:
r is independently an integer from 35-55, inclusive; and
the plurality of compounds has a purity of 87% or greater with respect to compounds of Formula (I).

### Claim 2 (depends on 1)

The plurality of compounds of claim 1, wherein r is independently an integer from 40-50, inclusive.

### Claim 3 (depends on 1)

The plurality of compounds of claim 1, wherein r is independently an integer from 42-48, inclusive.

### Claim 4 (depends on 1)

The plurality of compounds of claim 1, wherein r is independently an integer from 44-46, inclusive.

### Claim 5 (depends on 1)

The plurality of compounds of claim 1, wherein r is 45.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is greater than 87%.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is greater than 90%.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is greater than 95%.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is greater than 98%.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is greater than 99%.

### Claim 11 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is from 90-100%, inclusive.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is from 90-95%, inclusive.

### Claim 13 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, wherein the purity is from 95-100%, inclusive.

### Claim 14 (depends on 1, 2, 3, 4, 5)

The plurality of compounds of any one of claims 1-5, comprising less than 13% of total impurities, wherein the impurities are one or more of the following:
or salts thereof, wherein r is independently an integer from 35-55, inclusive.

### Claim 15 (depends on 15)

The plurality of compounds of claim 15, comprising less than 10% of total impurities.

### Claim 16 (depends on 15)

The plurality of compounds of claim 15, comprising less than 5% of total impurities.

### Claim 17 (depends on 15)

The plurality of compounds of claim 15, comprising less than 2% of total impurities.

### Claim 18 (depends on 15)

The plurality of compounds of claim 15, comprising less than 1% of total impurities.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, consisting of compounds of Formula (I).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, consisting essentially of compounds of Formula (I).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, substantially free of impurities.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, substantially free of the one or more impurities recited in claim 18.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, substantially free of PEG.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, substantially free of lipids other than compounds of Formula (I).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The plurality of compounds of any one of claims 1-18, substantially free of fatty acids.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A lipid nanoparticle (LNP) comprising a plurality of compounds of any one of claims 1-25.

### Claim 27

A lipid nanoparticle (LNP) comprising a plurality of PEG lipids, wherein the plurality of PEG lipids has a purity of 87% or greater with respect to the PEG lipid component of the LNP.

### Claim 28 (depends on 27)

The LNP of claim 27, wherein the purity is greater than 87%.

### Claim 29 (depends on 27, 28)

The LNP of claim 27 or 28, wherein the purity is greater than 90%.

### Claim 30 (depends on 27)

The LNP of any one of claim 27, wherein the purity is greater than 95%.

### Claim 31 (depends on 27, 28, 29, 30)

The LNP of any one of claims 27-30, wherein the purity is greater than 98%.

### Claim 32 (depends on 27, 28, 29, 30, 31)

The LNP of any one of claims 27-31, wherein the purity is greater than 99%.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

The LNP of any one of claims 27-32, wherein the purity is from 90-100%, inclusive.

### Claim 34 (depends on 27, 28, 29, 30, 31, 32, 33)

The LNP of any one of claims 27-33, wherein the purity is from 90-95%, inclusive.

### Claim 35 (depends on 27, 28, 29, 30, 31, 32, 33, 34)

The LNP of any one of claims 27-34, wherein the purity is from 95-100%, inclusive.

### Claim 36 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35)

The LNP of any one of claims 27-35, wherein the plurality of PEG lipids comprises one of more PEG lipids of Formula (V):
or a salts thereof, wherein:
R3 is —ORO;
RO is hydrogen, optionally substituted alkyl or an oxygen protecting group;
r is an integer between 1 and 100, inclusive;
R5 is optionally substituted C10-40 alkyl, optionally substituted C10-40 alkenyl, or optionally substituted C10-40 alkynyl; and optionally one or more methylene groups of R5 are replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN)—, —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RN)—, —C(S)—, —C(S)N(RN)—, —NRNC(S)—, —NRNC(S)N(RN)—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O)2—, —S(O)2O—, —OS(O)2O—, —N(RN)S(O)—, —S(O)N(RN)—, —N(RN)S(O)N(RN)—, —OS(O)N(RN)—, —N(RN)S(O)O—, —S(O)2—, —N(RN)S(O)2—, —S(O)2N(RN)—, —N(RN)S(O)2N(RN)—, —OS(O)2N(RN)—, or —N(RN)S(O)2O—; and
each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group.

### Claim 37 (depends on 36)

The LNP of claim 36, wherein the PEG lipid is of the following formula:
or a salt thereof, wherein r is independently an integer from 35-55, inclusive.

### Claim 38 (depends on 36)

The LNP of claim 36, wherein the PEG lipid is of the following formula:
or a salt thereof, wherein r is independently an integer from 35-55, inclusive.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The LNP of claim 26, wherein the plurality of compounds of any one of claims 1-25 is present in a molar ratio of 0.15-15% with respect to other lipids.

### Claim 40 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The LNP of any one of claims 27-38, wherein the LNP comprises about 0.15-15% of the plurality of PEG lipids.

### Claim 41 (depends on 39, 40)

The LNP of claim 39 or 40, wherein the LNP comprises about 1-2% of the plurality of PEG lipids.

### Claim 42 (depends on 39, 40)

The LNP of claim 39 or 40, wherein the LNP comprises about 1-2% of the plurality of PEG lipids.

### Claim 43 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The LNP of any one of claims 26-42 further comprising an ionizable amino lipid.

### Claim 44 (depends on 43)

The LNP of claim 43, wherein the ionizable amino lipid is a compound of a compound of Formula (X):
or a salt or isomer thereof, wherein:
R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, C2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
R4 is selected from the group consisting of a C3-6 carbocycle, —(CH2)nQ, —(CH2)nCHQR, —CHQR, —CQ(R)2, and unsubstituted C1-6 alkyl, where Q is selected from a carbocycle, heterocycle, —OR, —O(CH2)nN(R)2, —C(O)OR, —OC(O)R, —CX3, —CX2H, —CXH2, —CN, —N(R)2, —C(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, —N(R)R8, —O(CH2)nOR, —N(R)C(═NR9)N(R)2, —N(R)C(═CHR9)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)2R, —N(OR)C(O)OR, —N(OR)C(O)N(R)2, —N(OR)C(S)N(R)2, —N(OR)C(═NR9)N(R)2, —N(OR)C(═CHR9)N(R)2, —C(═NR9)N(R)2, —C(═NR9)R, —C(O)N(R)OR, and —C(R)N(R)2C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;
each R5 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R6 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2—, —S—S—, an aryl group, and a heteroaryl group;
R7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
R8 is selected from the group consisting of C3-6 carbocycle and heterocycle;
R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl, —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and heterocycle;
each R is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R′ is independently selected from the group consisting of C1-18alkyl, C2-18 alkenyl, —R*YR″, —YR″, and H;
each R″ is independently selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each Y is independently a C3-6 carbocycle;
each X is independently selected from the group consisting of F, Cl, Br, and I; and
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

### Claim 45 (depends on 43, 44)

The LNP of claim 43 or 44, wherein the ionizable amino lipid is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 46 (depends on 43, 44)

The LNP of claim 43 or 44, wherein the ionizable amino lipid is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 47 (depends on 43, 44)

The LNP of claim 43 or 44, wherein the ionizable amino lipid is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 48 (depends on 43)

The LNP of claim 43, wherein the ionizable amino lipid is of Formula (Y):
or a salt thereof, wherein:
Ring A is
A1 and A2 are each independently selected from CH and N;
Z is CH2 or absent wherein when Z is CH2, the dashed lines (1) and (2) each represent a single bond; and when Z is absent, the dashed lines (1) and (2) are both absent;
R1, R2, R3, R4, and R5 are independently selected from the group consisting of C5-20 alkyl, C5-20 alkenyl, —R″MR′, —R*YR″, —YR″, and —R*OR″;
each M is independently selected from the group consisting of —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2—, an aryl group, and a heteroaryl group;
X1, X2, and X3 are independently selected from the group consisting of a bond, —CH2—, —(CH2)2—, —CHR—, —CHY—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)—CH2—, —CH2C(O)—, —C(O)O—CH2—, —OC(O)—CH2—, —CH2C(O)O—, —CH2OC(O)—, —CH(OH)—, —C(S)—, and —CH(SH)—;
each Y is independently a C3-6 carbocycle;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each R is independently selected from the group consisting of C1-3 alkyl and a C3-6 carbocycle;
each R′ is independently selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, and H; and
each R″ is independently selected from the group consisting of C3-12 alkyl and C3-12 alkenyl.

### Claim 49 (depends on 48)

The LNP of claim 48, wherein the ionizable amino lipid is of the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The LNP of claim any one of claims 43-49, wherein the ionizable amino lipid is present in a molar ratio of about 25-65% with respect to other lipids.

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49)

The LNP of claim any one of claims 43-49, wherein the ionizable amino lipid is present in a molar ratio of about 40% or less with respect to other lipids.

### Claim 52 (depends on 43, 44, 45, 46, 47, 48, 49)

The LNP of any one of claims 43-49, wherein the ionizable amino lipid is present in a molar ratio of about 25-40% or less with respect to other lipids

### Claim 53 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The LNP of any one of claims 26-52 further comprising a helper lipid.

### Claim 54 (depends on 53)

The LNP of claim 53, wherein the helper lipid is DSPC or an analog thereof.

### Claim 55 (depends on 54)

The LNP of claim 54, wherein the helper lipid is DSPC.

### Claim 56 (depends on 54)

The LNP of claim 54, wherein the helper lipid is of the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 57 (depends on 54)

The LNP of claim 54, wherein the helper lipid is DOPE.

### Claim 58 (depends on 53)

The LPN of claim 53, wherein the helper lipid is oleic acid or an analog thereof.

### Claim 59 (depends on 53, 54, 55, 56, 57, 58)

The LNP of any one of claims 53-58, wherein the helper lipid is present in a molar ratio of about 10-40% with respect to other lipids.

### Claim 60 (depends on 59)

The LNP of claim 59, wherein the helper lipid is present in a molar ratio of about 30% with respect to other lipids.

### Claim 61 (depends on 59)

The LNP of claim 59, wherein the helper lipid is present in a molar ratio of about 20% with respect to other lipids.

### Claim 62 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The LNP of any one of claims 26-61 further comprising a structural lipid.

### Claim 63 (depends on 62)

The LNP of claim 62, wherein the structural lipid is a sterol.

### Claim 64 (depends on 63)

The LNP of claim 63, wherein the structural lipid is cholesterol.

### Claim 65 (depends on 62, 63, 64)

The LNP of any one of claims 62-64, wherein the structural lipid is present in a molar ratio of about 30-50% with respect to other lipids.

### Claim 66 (depends on 65)

The LNP of any one of claim 65, wherein the structural lipid is present in a molar ratio of about 38.5% with respect to other lipids.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The LNP of any one of claims 26-66 comprising a plurality of compounds of any one of claims 1-25, an ionizable amino lipid, a helper lipid, and a structural lipid.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The LNP of any one of claims 26-67 comprising a molar ratio of about 25-65% ionizable amino lipid, about 0.15-15% of the plurality of compounds of any one of claims 1-25, about 30-50% structural lipid, and about 10-40% helper lipid.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A lipid nanoparticle (LNP) comprising Compound (A):
a plurality of compounds of Formula (I) of any one of claims 1-25, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol.

### Claim 70 (depends on 69)

The LNP of claim 69, wherein Compound (A) is present in a molar ratio of 40% or less with respect to other lipids.

### Claim 71 (depends on 69, 70)

The LNP of claim 69 or 70, wherein Compound (A) is present in a molar ratio of 25-35%, inclusive, with respect to other lipids.

### Claim 72 (depends on 69, 70, 71)

The LNP of any one of claims 69-71, wherein Compound (A) is present in a molar ratio of approximately 30%, with respect to other lipids.

### Claim 73 (depends on 69, 70, 71, 72)

The LNP of any one of claims 69-72, wherein the compounds of Formula (I) are present in a molar ratio of 0.15-15% with respect to other lipids.

### Claim 74 (depends on 69, 70, 71, 72, 73)

The LNP of any one of claims 69-73, wherein the compounds of Formula (I) are present in a molar ratio of 1-2% with respect to other lipids.

### Claim 75 (depends on 69, 70, 71, 72, 73, 74)

The LNP of any one of claims 69-74, wherein the compounds of Formula (I) are present in a molar ratio of approximately 1.5% with respect to other lipids.

### Claim 76 (depends on 69, 70, 71, 72, 73, 74, 75)

The LNP of any one of claims 69-75, wherein DOPE is present in a molar ratio of 20-40% with respect to other lipids.

### Claim 77 (depends on 69, 70, 71, 72, 73, 74, 75, 76)

The LNP of any one of claims 69-76, wherein DOPE is present in a molar ratio of approximately 30% with respect to other lipids.

### Claim 78 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77)

The LNP of any one of claims 69-77, wherein cholesterol is present in a molar ratio of 30-50% with respect to other lipids.

### Claim 79 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The LNP of any one of claims 69-78, wherein cholesterol is present in a molar ratio of approximately 38.5% with respect to other lipids.

### Claim 80 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The LNP of any one of claims 69-79 comprising a molar ratio of 40% or less of Compound (A), 0.15-15% compounds of Formula (I), 20-40% DOPE, and 30-50% cholesterol.

### Claim 81 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The LNP of any one of claims 69-80 comprising a molar ratio of 25-35% Compound (A), 1-2% compounds of Formula (I), 25-35% DOPE, and 35-42% cholesterol.

### Claim 82 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The LNP of any one of claims 69-81 comprising Compound (A):compounds of Formula (I):DOPE:cholesterol in a molar ratio of approximately 30:30:38.5:1.5.

### Claim 83 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The LNP of any one of claims 69-82 comprising Compound (A):compounds of Formula (I):DOPE:cholesterol in a molar ratio of approximately 40:20:38.5:1.5.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A lipid nanoparticle (LNP) comprising Compound (B):
a plurality of compounds of Formula (I) of any one of claims 1-25, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and cholesterol.

### Claim 85 (depends on 84)

The LNP of claim 84, wherein Compound (B) is present in a molar ratio of 30-45% with respect to other lipids.

### Claim 86 (depends on 84)

The LNP of claim 84, wherein Compound (B) is present in a molar ratio of 40% or less with respect to other lipids.

### Claim 87 (depends on 84, 85, 86)

The LNP of any one of claims 84-86, wherein Compound (B) is present in a molar ratio of 25-35%, inclusive with respect to other lipids.

### Claim 88 (depends on 84, 85, 86, 87)

The LNP of any one of claims 84-87, wherein Compound (B) is present in a molar ratio of approximately 30% with respect to other lipids.

### Claim 89 (depends on 84, 85, 86, 87, 88)

The LNP of any one of claims 84-88, wherein the compounds of Formula (I) are present in a molar ratio of 0.15-15% with respect to other lipids.

### Claim 90 (depends on 84, 85, 86, 87, 88, 89)

The LNP of any one of claims 84-89, wherein the compounds of Formula (I) are present in a molar ratio of 1-2% with respect to other lipids.

### Claim 91 (depends on 84, 85, 86, 87, 88, 89, 90)

The LNP of any one of claims 84-90, wherein the compounds of Formula (I) are present in a molar ratio of approximately 1.5% with respect to other lipids.

### Claim 92 (depends on 84, 85, 86, 87, 88, 89, 90, 91)

The LNP of any one of claims 84-91, wherein DOPE is present in a molar ratio of 20-40% with respect to other lipids.

### Claim 93 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92)

The LNP of any one of claims 84-92, wherein DOPE is present in a molar ratio of approximately 30% with respect to other lipids.

### Claim 94 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The LNP of any one of claims 84-93, wherein cholesterol is present in a molar ratio of 30-50% with respect to other lipids.

### Claim 95 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The LNP of any one of claims 84-94, wherein cholesterol is present in a molar ratio of approximately 38.5% with respect to other lipids.

### Claim 96 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The LNP of any one of claims 84-95 comprising a molar ratio of 40% or less of Compound (B), 0.15-15% compounds of Formula (I), 20-40% DOPE, and 30-50% cholesterol.

### Claim 97 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The LNP of any one of claims 84-96 comprising a molar ratio of 25-35% Compound (B), 1-2% compounds of Formula (I), 25-35% DOPE, and 35-42% cholesterol.

### Claim 98 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The LNP of any one of claims 84-97 comprising Compound (B):compounds of Formula (I):DOPE:cholesterol in a molar ratio of approximately 30:30:38.5:1.5.

### Claim 99 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The LNP of any one of claims 84-98 comprising Compound (B):compounds of Formula (I):DOPE:cholesterol in a molar ratio of approximately 40:20:38.5:1.5.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A lipid nanoparticle (LNP) comprising Compound (C):
a plurality of compounds of Formula (I) of any one of claims 1-25, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and cholesterol.

### Claim 101 (depends on 100)

The LNP of claim 100, wherein Compound (C) is present in a molar ratio of 30-45% with respect to other lipids.

### Claim 102 (depends on 100)

The LNP of claim 100, wherein Compound (C) is present in a molar ratio of 40% or less with respect to other lipids.

### Claim 103 (depends on 100, 101, 102)

The LNP of any one of claims 100-102, wherein Compound (C) is present in a molar ratio of 25-35%, inclusive, with respect to other lipids.

### Claim 104 (depends on 100, 101, 102, 103)

The LNP of any one of claims 100-103, wherein Compound (C) is present in a molar ratio of approximately 30% with respect to other lipids.

### Claim 105 (depends on 100, 101, 102, 103, 104)

The LNP of any one of claims 100-104, wherein the Compound of Formula (I) is present in a molar ratio of 0.15-15% with respect to other lipids.

### Claim 106 (depends on 100, 101, 102, 103, 104, 105)

The LNP of any one of claims 100-105, wherein the Compound of Formula (I) is present in a molar ratio of 1-2% with respect to other lipids.

### Claim 107 (depends on 100, 101, 102, 103, 104, 105, 106)

The LNP of any one of claims 100-106, wherein the Compound of Formula (I) is present in a molar ratio of approximately 1.5% with respect to other lipids.

### Claim 108 (depends on 100, 101, 102, 103, 104, 105, 106, 107)

The LNP of any one of claims 100-107, wherein DOPE is present in a molar ratio of 20-40% with respect to other lipids.

### Claim 109 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108)

The LNP of any one of claims 100-108, wherein DOPE is present in a molar ratio of approximately 30% with respect to other lipids.

### Claim 110 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The LNP of any one of claims 100-109, wherein cholesterol is present in a molar ratio of 30-50% with respect to other lipids.

### Claim 111 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The LNP of any one of claims 100-110, wherein cholesterol is present in a molar ratio of approximately 38.5% with respect to other lipids.

### Claim 112 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The LNP of any one of claims 100-111 comprising a molar ratio of 40% or less of Compound (C), 0.15-15% compounds of Formula (I), 20-40% DOPE, and 30-50% cholesterol.

### Claim 113 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The LNP of any one of claims 100-112 comprising a molar ratio of 25-35% Compound (C), 1-2% compounds of Formula (I), 25-35% DOPE, and 35-42% cholesterol.

### Claim 114 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The LNP of any one of claims 100-113 comprising Compound (C):compounds of Formula (I):DOPE:cholesterol in a molar ratio of approximately 30:30:38.5:1.5.

### Claim 115 (depends on 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The LNP of any one of claims 100-114 comprising Compound (C):compounds of Formula (I):DOPE:cholesterol in a molar ratio of approximately 40:20:38.5:1.5.

### Claim 116 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The LNP of any one of claims 26-115 further comprising a therapeutic agent.

### Claim 117 (depends on 116)

The LNP of claim 116, wherein the therapeutic agent is a nucleic acid.

### Claim 118 (depends on 116)

The LNP of claim 116, wherein the therapeutic agent is an RNA.

### Claim 119 (depends on 116)

The LNP of claim 116, wherein the therapeutic agent is an mRNA.

### Claim 120 (depends on 116, 117, 118, 119)

The LNP of any one of claims 116-119, wherein the LNP has an N/P ratio of from 2.0 to 5.0, inclusive.

### Claim 121 (depends on 120)

The LNP of claim 120, wherein the N/P ratio of from 2.5 to 3.5.

### Claim 122 (depends on 121)

The LNP of claim 121, wherein the N/P ratio is approximately 3.0.

### Claim 123 (depends on 116, 117, 118, 119, 120, 121, 122)

The LNP of any one of claims 116-122 further comprising an agent that inhibits an immune response in a subject.

### Claim 124 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The LNP of any one of claims 26-123, wherein the LNP formulation exhibits lower IgM binding as compared to an LNP formulation comprising a plurality of compounds of Formula (I) with a purity of less than 87%.

### Claim 125 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The LNP of any one of claims 26-123, wherein the LNP formulation exhibits higher ApoE binding as compared to an LNP formulation comprising a plurality of compounds of Formula (I) with a purity of less than 87%.

### Claim 126 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The LNP of any one of claims 26-123, wherein the LNP formulation is less sensitive to accelerated blood clearance (ABC) as compared to an LNP formulation comprising a plurality of compounds of Formula (I) with a purity of less than 87%.

### Claim 127 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A pharmaceutical composition comprising a plurality of compounds of any one of claims 1-25.

### Claim 128 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A cosmetic composition comprising a plurality of compounds of any one of claims 1-25.

### Claim 129 (depends on 26, 126)

A method of delivering a therapeutic agent to a subject, the method comprising administering to the subject an LNP of any one of claims 26-126; wherein the LNP encapsulates the therapeutic agent of interest.

### Claim 130

A method of preparing a compound of Formula (I):
or a salt thereof, the method comprising reacting a compound of the formula:
or a salt thereof, with a compound of the formula:
or a salt thereof; wherein r is an integer from 35-55, inclusive.

### Claim 131 (depends on 130)

The method of claim 130, wherein the reaction is carried out in the presence of a carboxyl activating reagent.

### Claim 132 (depends on 131)

The method of claim 131, wherein the reaction is carried out in the presence of a carbodiimide.

### Claim 133 (depends on 132)

The method of claim 132, wherein the reaction is carried out in the presence of EDC.HCl.

### Claim 134 (depends on 130, 131, 132, 133)

The method of any one of claims 130-133, wherein the reaction is carried out in the presence of a base.

### Claim 135 (depends on 134)

The method of claim 134, wherein the base is a pyridine base.

### Claim 136 (depends on 135)

The method of claim 135, wherein the base is DMAP.

### Claim 137 (depends on 130, 131, 132, 133, 134, 135, 136)

The method of any one of claims 130-136, wherein the reaction is carried out in the presence of EDC.HCl and DMAP.

### Claim 138 (depends on 130, 131, 132, 133, 134, 135, 136, 137)

The method of any one of claims 130-137, wherein the reaction is carried out in a solvent.

### Claim 139 (depends on 138)

The method of claim 138, wherein the solvent is DCM.

### Claim 140 (depends on 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

The method of any one of claims 130-139, wherein the reaction is carried out at a temperature ranging from approximately 0° C. to approximately 20° C.

### Claim 141 (depends on 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140)

The method of any one of claims 130-140 further comprising purifying the compounds of Formula (I) or salts thereof.

### Claim 142 (depends on 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

The method of any one of claims 130-141, wherein the compounds of Formula (I), or salts thereof, are isolated in a purity of at least 87% after purification.
